North Dakota State Investment Board grew its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 54,228 shares of the company’s stock after acquiring an additional 2,031 shares during the period. AbbVie comprises about 0.6% of North Dakota State Investment Board’s portfolio, making the stock its 25th largest holding. North Dakota State Investment Board’s holdings in AbbVie were worth $14,186,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the stock. State Street Corp raised its position in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after purchasing an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of AbbVie during the second quarter valued at $2,905,952,000. Deutsche Bank AG boosted its position in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after purchasing an additional 1,241,587 shares during the period. Finally, Amundi boosted its position in shares of AbbVie by 2.4% in the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after purchasing an additional 247,689 shares during the period. 70.23% of the stock is owned by institutional investors.
AbbVie Stock Down 0.1%
Shares of NYSE:ABBV opened at $286.10 on Thursday. The company’s fifty day moving average is $268.20 and its two-hundred day moving average is $236.51. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The company has a market cap of $505.47 billion, a P/E ratio of 80.82, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24.
AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 13.92 earnings per share for the current year.
AbbVie Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.
Insider Transactions at AbbVie
In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.
AbbVie News Summary
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie submitted a Biologics License Application to the FDA for etentamig, a monthly-dosed BCMA x CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. The Phase 3 CERVINO study reportedly delivered statistically significant improvements in overall response rate and progression-free survival versus standard therapies, adding a potential growth product to AbbVie’s oncology pipeline. AbbVie Submits BLA for Etentamig
- Positive Sentiment: AbbVie’s growth drivers remain in focus. Skyrizi and Rinvoq are expected to help offset Humira’s decline, while the FDA’s approval of a subcutaneous induction option for Skyrizi in Crohn’s disease could improve convenience and broaden adoption through at-home treatment. Skyrizi Crohn’s Disease Approval
- Neutral Sentiment: Investors are preparing for AbbVie’s third-quarter results, with attention on Skyrizi and Rinvoq sales, expense trends, updated guidance, and the sustainability of earnings growth. The company previously reported quarterly revenue and adjusted earnings above consensus expectations.
- Negative Sentiment: Analysts continue to debate whether ABBV is fully valued after a strong rally. Its elevated valuation leaves less room for disappointment, while rising expenses, softer estimates, and intensifying competition could pressure near-term results. AbbVie Patent Cliff Analysis
- Negative Sentiment: The company’s dividend appeal faces a longer-term test as investors seek evidence that Skyrizi and Rinvoq can replace lost Humira revenue and support continued payout growth. High Treasury yields also make income-oriented stocks compete harder for investor capital.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. Leerink Partners upped their price objective on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 target price on shares of AbbVie in a research report on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.86.
Read Our Latest Analysis on AbbVie
About AbbVie
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Read More
- Five stocks we like better than AbbVie
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
